Exploiting common genetic variation to make anticoagulation safer.
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000235:genetics; D000925:Anticoagulants / Q000009:adverse effects*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D001777:Blood Coagulation / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005260:Female; D014644:Genetic Variation / Q000235:genetics*; D006801:Humans; D020300:Intracranial Hemorrhages / Q000453:epidemiology / Q000517:prevention & control; D008297:Male; D006899:Mixed Function Oxygenases / Q000235:genetics; D012307:Risk Factors; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000009:adverse effects
D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D064417:Vitamin K Epoxide Reductases